https://pharmaphorum.com/news/beigenes-brukinsa-tops-imbruvica-in-head-to-head-contest
BeiGene's Brukinsa tops Imbruvica in head-to-head contest | pharmaphorum
beigenebrukinsatopsimbruvicahead
https://dailyaibrief.com/news/nference-beigene-collaborate-b-cell-cancer-research-qHEj0qwL
nference and BeiGene Collaborate on B-Cell Cancer Research - Daily AI Brief
nference and BeiGene have announced a collaboration to enhance research on B-cell cancers using AI technology, focusing on chronic lymphocytic leukemia and...
https://www.bmpharmaceuticals.com/novartis-beigenes-pd-1-hits-goal-in-first-line-liver-cancer-should-roche-worry-about-tecentriq/
Novartis, BeiGene's PD-1 hits goal in first-line liver cancer. Should Roche worry about Tecentriq?...
https://www.cliniexpert.com/article/409.html
BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of...
BeiGene, Ltd. today announced results from a Phase 3 clinical trial evaluating its anti-PD-1 antibody tislelizumab in combination with standard chemotherapy...
https://www.oncologyeducation.com/videos/best-of-hematology-conference-2025-beigene-breakfast-symposium-current-perspectives-in-the-management-of-cll-dr-christopher-hillis-dr-alina-gerrie/
Best of Hematology Conference 2025: BeiGene Breakfast Symposium: Current Perspectives in the...
best of
https://www.tradingkey.com/markets/stocks/nasdaq-onc
Beigene Ltd Today's Market Trends | ONC Stock Real-Time Quotes, Trading Strategies & Related...
Explore the ONC stock price trend chart, historical data trends, technical indicators, forecasts, and Beigene Ltd trading strategies and analysis.
https://www.benzinga.com/analyst-ratings/23/09/34493938/the-latest-analyst-ratings-for-beigene
The Latest Analyst Ratings for BeiGene - Benzinga
the latestanalyst ratingsbeigenebenzinga
https://www.biospace.com/beigene-announces-inclusion-in-the-china-national-reimbursement-drug-list-nrdl-of-tislelizumab-in-three-new-indications-brukinsa-zanubrutinib-in-one-new-indication-and-the-first-listing-for-pamiparib
BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in...
Dec 3, 2021 - BeiGene, a global science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for...
https://www.dcatvci.org/top-industry-news/bi-beigene-in-supply-pact/
BI, BeiGene in Supply Pact - DCAT Value Chain Insights
Sep 8, 2021 - Boehringer Ingelheim (BI) and BeiGene, a Beijing, China-headquartered clinical-stage biopharmaceutical company focused on immuno-oncology, have signed a...
value chainbibeigenesupplypact